Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.62 |
| ▸ | PTGIR | P43119 | 2/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781551 | 0.98 | PTGS2 (0.64) | PTGS2PTGS1PTGIRPTGDR | |
| SCHEMBL5778098 | 0.97 | PTGS2 (0.66) | PTGS2PTGS1PTGIRPTGDR | |
| SCHEMBL3943725 | 0.96 | PTGS2 (0.64) | PTGS2PTGS1PTGIR | |
| SCHEMBL5779766 | 0.96 | PTGS2 (0.64) | PTGS2PTGS1PTGIR | |
| SCHEMBL3950144 | 0.85 | PTGS2 (0.52) | PTGS2PTGS1PTGIRPTGDR | |
| SCHEMBL5780346 | 0.83 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL3938976 | 0.82 | PTGIR (0.50) | PTGS2PTGS1PTGIRPTGDR | |
| SCHEMBL5781556 | 0.81 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL5781225 | 0.81 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL5777146 | 0.81 | PTGS2 (0.54) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005460-B1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LAB (US) | 2006-03-08 | — | — | EP | claimed |
| US-20030105101-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-06-05 | — | — | US | claimed |
| US-6525053-B1 | 2-Benzyl-5-(4-methylsulfonylphenyl)-6-(4-fluorophenyl)-3(2H) -pyridazinone; cyclooxygenase (COX) inhibitors pain, fever, inflammation, rheumatoid arthritis, osteoarthritis; minimizes GI and renal side-effects | ABBOTT LABORATORIES | 2003-02-25 | — | — | US | claimed |
| EP-1005460-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010332-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | claimed |
| EP-1005460-B1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LAB (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20030105101-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-06-05 | — | — | US | disclosed |
| US-6525053-B1 | 2-Benzyl-5-(4-methylsulfonylphenyl)-6-(4-fluorophenyl)-3(2H) -pyridazinone; cyclooxygenase (COX) inhibitors pain, fever, inflammation, rheumatoid arthritis, osteoarthritis; minimizes GI and renal side-effects | ABBOTT LABORATORIES | 2003-02-25 | — | — | US | disclosed |
| EP-1005460-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010332-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105101-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGIS, PTGES2, PTGS2 | PTGS2 3/4885PTGS1 4/4885PTGIR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.